Raphael Pharma dismisses Deloitte auditor, Chairman Press resigns; new exec comp agreements

Raphael Pharmaceutical Inc.

Dismissed Brightman Almagor Zohar (Deloitte) as auditor; appointed Weinstein International as new independent auditor.
Chairman Prof. Joseph Press resigned from board effective June 30, 2022; consulting fee $1,000/meeting, 280k shares, 105k warrants at $1.12.
CEO Shlomo Pilo (Sheffa Enterprises) gets new management agreement: $10k/mo (2022) then $20k/mo, 1M warrants at $1.12, expires Dec 2024.
CFO Guy Ofir gets operations agreement: $6k/mo (2022) then $12k/mo, 1M restricted shares, 1M warrants at $1.00, expires Dec 2024.
CTO Dr. Igal Louria Hayon: $9k/mo (2022) then $12k/mo, 990k warrants at $0.01, plus 15% of royalties from cannabis COVID and RA indications.

item 4.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Joseph Press

Chairman of the Board of Directors

RAPH · Raphael Pharmaceutical Inc.

Effective: 2022-06-30
Filed: July 7, 2022, 7:59 PM ET

On June 30, 2022, Prof. Joseph Press informed the Company that he intended to resign from the Board of Directors, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Joseph Press resigned as Chairman of the Board of Directors at Raphael Pharmaceutical Inc..

Action: resigned
Role: Chairman of the Board of Directors

Exact text from the filing

On June 30, 2022, Prof. Joseph Press informed the Company that he intended to resign from the Board of Directors, effective immediately.

View on SEC.gov

Raphael Pharmaceutical Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-037819

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.